Ranked #7,272 of 8,699 institutional investors
Birchview Capital, LP
Burlington, VT
$141M
US stock portfolio at live prices · today −$2.2M (−1.55%)
Market closed. Prices as of Nov 20, 7:11 AM ET
- Value at quarter end (Q3 2026)
- $173M
- Change from Q2 2026
- −$40.7M (−19.04%)
- Positions
- 68 · 15 new, 13 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$12.7M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKLAC 16.7%BMY 9.26%OVV 4.69%RARE 4.56%LRCX 4.33%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KLAC KLA Corporation | 166,938 | $23.6M | 16.7% | Reduced −6% |
| BMY Bristol-Myers Squibb Company | 224,245 | $13.1M | 9.26% | Reduced −25% |
| OVV Ovintiv Inc. | 107,500 | $6.6M | 4.69% | Unchanged |
| RARE Ultragenyx Pharmaceutical Inc. | 373,671 | $6.4M | 4.56% | New |
| LRCX Lam Research Corporation | 30,000 | $6.1M | 4.33% | Reduced −14% |
| SLDB Solid Biosciences Inc. | 715,955 | $4.6M | 3.26% | Added +7% |
| PTGX Protagonist Therapeutics, Inc. | 35,000 | $4.3M | 3.07% | Unchanged |
| NBIX Neurocrine Biosciences, Inc. | 25,190 | $3.9M | 2.79% | Reduced −7% |
| STOK Stoke Therapeutics, Inc. | 138,000 | $3.7M | 2.63% | Reduced −23% |
| CORT Corcept Therapeutics Incorporated | 55,200 | $3.6M | 2.54% | Reduced −3% |
| HALO Halozyme Therapeutics, Inc. | 33,351 | $3.1M | 2.20% | Added +0% |
| ACAD Acadia Pharmaceuticals Inc. | 171,000 | $3.0M | 2.13% | Unchanged |
| NTLA Intellia Therapeutics, Inc. | 281,365 | $2.7M | 1.90% | Reduced −27% |
| BDSX Biodesix, Inc. | 286,804 | $2.4M | 1.69% | Unchanged |
| ZBIO Zenas BioPharma, Inc. | 93,380 | $2.3M | 1.66% | Reduced −0% |
| BIIB Biogen Inc. | 9,000 | $2.2M | 1.57% | Unchanged |
| VIR Vir Biotechnology, Inc. | 226,992 | $2.0M | 1.43% | Added +3% |
| EQT EQT Corporation | 34,619 | $1.7M | 1.21% | Unchanged |
| ABVX ABIVAX Société Anonyme | 21,000 | $1.7M | 1.20% | Added +24% |
| IRLA IRulya Therapeutics Inc. | 40,601 | $1.6M | 1.15% | New |
| XENE Xenon Pharmaceuticals Inc. | 42,995 | $1.6M | 1.14% | Added +104% |
| CLDX Celldex Therapeutics, Inc. | 57,200 | $1.6M | 1.13% | Reduced −18% |
| CYTK Cytokinetics, Incorporated | 30,000 | $1.5M | 1.09% | Unchanged |
| DFTX Definium Therapeutics, Inc. | 52,000 | $1.5M | 1.09% | Added +160% |
| NKTR Nektar Therapeutics | 46,000 | $1.5M | 1.06% | Reduced −43% |
| BBIO BridgeBio Pharma, Inc. | 18,741 | $1.5M | 1.04% | Added +114% |
| UTHR United Therapeutics Corporation | 2,500 | $1.4M | 0.99% | Reduced −45% |
| RLMD Relmada Therapeutics, Inc. | 408,100 | $1.3M | 0.90% | Unchanged |
| TVTX Travere Therapeutics, Inc. | 25,000 | $1.2M | 0.86% | Reduced −14% |
| VALN Valneva SE | 201,390 | $1.1M | 0.77% | New |
| CMPX Compass Therapeutics, Inc. | 1,575,000 | $1.1M | 0.76% | Reduced −6% |
| IMNM Immunome, Inc. | 55,600 | $924K | 0.65% | Added +11% |
| FCX Freeport-McMoRan Inc. | 18,027 | $885K | 0.63% | Unchanged |
| ADAG Adagene Inc. | 430,000 | $864K | 0.61% | Added +79% |
| AXSM Axsome Therapeutics, Inc. | 6,000 | $814K | 0.58% | Unchanged |
| QDEL QuidelOrtho Corporation | 89,377 | $797K | 0.56% | Unchanged |
| HROW Harrow, Inc. | 24,000 | $771K | 0.55% | Unchanged |
| CSTL Castle Biosciences, Inc. | 22,935 | $766K | 0.54% | Added +77% |
| BLSM BlossomHill Therapeutics, Inc. | 50,000 | $721K | 0.51% | New |
| SLN Silence Therapeutics plc | 30,000 | $594K | 0.42% | Reduced −58% |
| LUNG Pulmonx Corporation | 200,000 | $548K | 0.39% | Reduced −0% |
| BCYC Bicycle Therapeutics plc | 176,432 | $538K | 0.38% | Reduced −44% |
| FHTX Foghorn Therapeutics Inc. | 282,307 | $503K | 0.36% | Added +0% |
| CAMP Camp4 Therapeutics Corp | 120,000 | $480K | 0.34% | Unchanged |
| VOR Vor Biopharma Inc. | 24,000 | $444K | 0.31% | New |
| OLMA Olema Oncology, Inc. | 59,000 | $422K | 0.30% | Reduced −70% |
| MLTX MoonLake Immunotherapeutics | 36,220 | $400K | 0.28% | New |
| VYGR Voyager Therapeutics, Inc. | 224,918 | $362K | 0.26% | Added +199% |
| TRIN Trinity Capital Inc. | 20,000 | $338K | 0.24% | Unchanged |
| CRMD CorMedix Inc. | 65,874 | $335K | 0.24% | New |
| DRUG Bright Minds Biosciences Inc. | 15,400 | $319K | 0.23% | New |
| AEMD Aethlon Medical, Inc. | 62,837 | $304K | 0.22% | New |
| PACB Pacific Biosciences of California, Inc. | 160,000 | $282K | 0.20% | Reduced −88% |
| RZLT Rezolute, Inc. | 60,296 | $253K | 0.18% | New |
| KBDC Kayne Anderson BDC, Inc. | 20,000 | $242K | 0.17% | Unchanged |
| ALT Altimmune, Inc. | 160,964 | $227K | 0.16% | Added +5% |
| ABEO Abeona Therapeutics Inc. | 90,700 | $222K | 0.16% | New |
| CGEM Cullinan Therapeutics, Inc. | 20,000 | $181K | 0.13% | Unchanged |
| TRDA Entrada Therapeutics, Inc. | 36,849 | $171K | 0.12% | New |
| IMUX Immunic, Inc. | 21,917 | $162K | 0.11% | New |
| ELUT Elutia Inc. | 165,094 | $134K | <0.1% | Unchanged |
| OCUL Ocular Therapeutix, Inc. | 20,450 | $120K | <0.1% | Reduced −1% |
| CRDL Cardiol Therapeutics Inc. | 100,000 | $88K | <0.1% | New |
| BMEA Biomea Fusion, Inc. | 93,500 | $55K | <0.1% | New |
| KYNB Kyntra Bio, Inc. | 22,566 | $41K | <0.1% | Unchanged |
| IVVD Invivyd, Inc. | 75,975 | $34K | <0.1% | Reduced −78% |
| LPCN Lipocine Inc. | 16,712 | $25K | <0.1% | Unchanged |
| DCGO DocGo Inc. | 39,062 | $7K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| VERA Vera Therapeutics, Inc. | 57,758 | $1.5M |
| NVO Novo Nordisk A/S | 24,000 | $933K |
| FDMT 4D Molecular Therapeutics, Inc. | 48,505 | $520K |
| SVRA Savara Inc. | 80,000 | $417K |
| GPCR Structure Therapeutics Inc. | 24,000 | $411K |
| BIOA BioAge Labs, Inc. | 69,000 | $325K |
| PHAT Phathom Pharmaceuticals, Inc. | 55,000 | $279K |
| CMPS COMPASS Pathways plc | 30,000 | $260K |
| CADL Candel Therapeutics, Inc. | 47,756 | $245K |
| GRCE Grace Therapeutics, Inc. | 120,000 | $208K |
| CAPR Capricor Therapeutics, Inc. | 14,352 | $108K |
| QNRX Quoin Pharmaceuticals, Ltd. | 20,000 | $67K |
| GOSS Gossamer Bio, Inc. | 227 | $3K |